Nordson’s second quarter results drew a strong positive market reaction, fueled by broad-based sales gains across all major business segments. Management pointed to particularly robust growth in the Advanced Technology and Medical segments, highlighting accelerated order momentum and a 35% year-over-year increase in backlog. CEO Sundaram Nagarajan emphasized the impact of the company’s Ascend Strategy and operational execution, stating, “We are winning due to our unique competitive advantages and the successful execution of our Ascend Strategy.” These factors led to record sales and profit performance, underpinned by strong cash conversion and margin expansion.
Is now the time to buy NDSN? Find out in our full research report (it’s free for active Edge members).
Nordson (NDSN) Q2 CY2026 Highlights:
- Revenue: $817.7 million vs analyst estimates of $780.2 million (10.3% year-on-year growth, 4.8% beat)
- Adjusted EPS: $3.25 vs analyst estimates of $3.09 (5% beat)
- Adjusted EBITDA: $262.5 million vs analyst estimates of $254.2 million (32.1% margin, 3.3% beat)
- The company lifted its revenue guidance for the full year to $3.06 billion at the midpoint from $2.97 billion, a 2.9% increase
- Management raised its full-year Adjusted EPS guidance to $11.90 at the midpoint, a 3% increase
- Operating Margin: 27.3%, up from 25.3% in the same quarter last year
- Organic Revenue rose 12% year on year (miss)
- Market Capitalization: $18.58 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Nordson’s Q2 Earnings Call
- Michael Halloran (Baird) asked about the context for Nordson’s backlog surge and potential lead time elongation. CFO Dan Hopgood explained that backlog growth is broad-based with no significant change in order patterns or lead times, and most backlog turns over within six months.
- Jeffrey Hammond (KeyBanc) questioned the outsized contribution of Advanced Technology Solutions to the earnings outlook. CEO Sundaram Nagarajan clarified that ATS is benefiting from peak-cycle demand, while Medical also contributed to the raised guidance, and Industrial Precision performed in line with expectations.
- Matt Summerville (D.A. Davidson) inquired about growth drivers within Medical and Fluid Solutions and expectations for the next quarter. Hopgood noted broad-based gains across medical components, interventional, and fluid products, with some areas already returning to historic growth rates and others still ramping.
- Christopher Glynn (Oppenheimer) sought details on new application opportunities in Industrial Precision Solutions. Nagarajan explained that IPS continues to pursue niche applications across sectors like batteries and data centers, but near-term growth is expected from incremental opportunities rather than major breakthroughs.
- Edward Magi (BNP Paribas) asked about the M&A pipeline and target areas. Nagarajan and Hopgood reiterated the company’s disciplined approach, with a focus on medical and test & inspection acquisitions, and a long-term goal of balancing organic and inorganic growth.
Catalysts in Upcoming Quarters
Looking forward, the StockStory team will be tracking (1) the pace and sustainability of order momentum in Advanced Technology Solutions, (2) normalization and growth trends within Medical and Fluid Solutions, and (3) evidence of operational improvements driving margin expansion across segments. The timing and scope of new chip manufacturing investments in North America could serve as a key incremental growth lever.
Nordson currently trades at $333.64, up from $309.92 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
Source link
Author

- Ytv Market News
- Share-market news writer and analyst with deep experience covering equities, commodities, forex, and cryptocurrencies for readers in the USA, UK, Canada, and Australia. Ytv Market News delivers timely market updates, practical trading insights, and clear explanations of macro and company-level catalysts that move prices. Combines on-the-ground financial reporting with technical analysis, using concise charts and actionable ideas to help investors and traders make smarter decisions.
Latest entries
Crypto NewsAugust 26, 2026Bitcoin +25%, Gold at 3-Month High: Why They’re Suddenly Buying the Same Fear
UsaAugust 26, 2026Peter Beck’s Neutron Rocket Could Slip to 2027. Here’s How Much the Delay Actually Matters.
AustraliaAugust 26, 2026La Trobe Private Credit Fund unveils August 2026 distribution and DRP details
Crypto NewsAugust 26, 2026Hyperliquid activates AQAv2 to fund HYPE buybacks
